Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Mitchell Diccianni

    TitleProject Scientist
    SchoolUniversity of California, San Diego
    DepartmentPediatrics
    Address200 W. Arbor Drive #8447
    CA San Diego 92103
    Phone619-543-2436
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni M, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017 Jul; 18(7):946-957. PMID: 28549783.
        View in: PubMed
      2. Batova A, Altomare D, Creek KE, Naviaux RK, Wang L, Li K, Green E, Williams R, Naviaux JC, Diccianni M, Yu AL. Englerin A induces an acute inflammatory response and reveals lipid metabolism and ER stress as targetable vulnerabilities in renal cell carcinoma. PLoS One. 2017; 12(3):e0172632. PMID: 28296891.
        View in: PubMed
      3. Williams RT, Yu AL, Diccianni M, Theodorakis EA, Batova A. Erratum: renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy. J Exp Clin Cancer Res. 2014; 33(1):95. PMID: 25480670.
        View in: PubMed
      4. Barnhill LM, Williams RT, Cohen O, Kim Y, Batova A, Mielke JA, Messer K, Pu M, Bao L, Yu AL, Diccianni M. High Expression of CAI2, a 9p21-Embedded Long Noncoding RNA, Contributes to Advanced-Stage Neuroblastoma. Cancer Res. 2014 Jul 15; 74(14):3753-63. PMID: 25028366.
        View in: PubMed
      5. Terme M, Dorvillius M, Cochonneau D, Chaumette T, Xiao W, Diccianni M, Barbet J, Yu AL, Paris F, Sorkin LS, Birklé S. Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia. PLoS One. 2014; 9(2):e87210. PMID: 24520328.
        View in: PubMed
      6. Williams RT, Barnhill LM, Kuo HH, Lin WD, Batova A, Yu AL, Diccianni M. Chimeras of p14ARF and p16: Functional Hybrids with the Ability to Arrest Growth. PLoS One. 2014; 9(2):e88219. PMID: 24505435.
        View in: PubMed
      7. Kelner MJ, Diccianni M, Yu AL, Rutherford MR, Estes LA, Morgenstern R. Absence of MGST1 mRNA and protein expression in human neuroblastoma cell lines and primary tissue. Free Radic Biol Med. 2014 Apr; 69:167-71. PMID: 24486338.
        View in: PubMed
      8. Williams RT, Yu AL, Diccianni M, Theodorakis EA, Batova A. Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy. J Exp Clin Cancer Res. 2013; 32(1):57. PMID: 23958461.
        View in: PubMed
      9. Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, Diccianni M, London WB, Chang CH, Yu AL. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 2010 Oct 15; 70(20):7841-50. PMID: 20805302.
        View in: PubMed
      10. Lo TC, Barnhill LM, Kim Y, Nakae EA, Yu AL, Diccianni M. Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk Res. 2009 Nov; 33(11):1562-6. PMID: 19473701.
        View in: PubMed
      11. Yang HC, Huang MC, Li LH, Lin CH, Yu AL, Diccianni M, Wu JY, Chen YT, Fann CS. MPDA: microarray pooled DNA analyzer. BMC Bioinformatics. 2008; 9:196. PMID: 18412951.
        View in: PubMed
      12. Batova A, Cottam H, Yu J, Diccianni M, Carrera CJ, Yu AL. EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. Blood. 2006 Feb 1; 107(3):898-903. PMID: 16234352.
        View in: PubMed
      13. Gebauer S, Yu AL, Omura-Minamisawa M, Batova A, Diccianni M. Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma. Genes Chromosomes Cancer. 2004 Dec; 41(4):297-308. PMID: 15390183.
        View in: PubMed
      14. Diccianni M, Yu J, Meppelink G, de Vries M, Shao L, Gebauer S, Shih H, Roberts W, Kilcoin NP, Pullen J, Carson DA, Yu AL. 3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner. J Exp Ther Oncol. 2004 Oct; 4(3):223-37. PMID: 15724842.
        View in: PubMed
      15. Batova A, Shao LE, Diccianni M, Yu AL, Tanaka T, Rephaeli A, Nudelman A, Yu J. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood. 2002 Nov 1; 100(9):3319-24. PMID: 12384433.
        View in: PubMed
      16. Broome HE, Yu AL, Diccianni M, Camitta BM, Monia BP, Dean NM. Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. Leuk Res. 2002 Mar; 26(3):311-6. PMID: 11792421.
        View in: PubMed